Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature

Orly Haskin, Yafa Falush, Miriam Davidovits

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery. Case-diagnosis/treatment: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis. Conclusion: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.

Original languageEnglish
Pages (from-to)2601-2604
Number of pages4
JournalPediatric Nephrology
Volume34
Issue number12
DOIs
StatePublished - 1 Dec 2019

Keywords

  • Child
  • Dialysis
  • Eculizumab
  • aHUS

Fingerprint

Dive into the research topics of 'Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature'. Together they form a unique fingerprint.

Cite this